Data show benefits of combination antibiotic therapy

pharmafield logo - pharma news

Helperby Therapeutics Ltd has presented data from Phase I results on the tolerability, pharmacokinetics, pharmacodynamics and efficacy of AZT and colistin both alone and as a combined therapy, against multi-drug resistant Enterobacteriaceae (CRE), one of the most serious drug resistant pathogens.

The company also presented preclinical data which shows that AZT is active against carbapenem and colistin resistant Enterobacteriaceae. AZT is a DNA chain terminator and represents a new class of antibacterial agent against the most resistant Gram-negative bacteria.

This research paves the way for further clinical trials and the potential for the development of a new class of antibiotics, effective against some of the most resistant pathogens.

The combination provides antibiotic enhancement with a low dose of colistin, which is safe and tolerable in humans as demonstrated by the phase 1 results, and so avoids the risk of renal toxicity associated with colistin in higher doses.

Helperby’s new class of ARB antibiotic therapy is one of only a handful of drug candidates that the World Health Organisation has identified as in development to tackle the three WHO Critical Priority pathogens; Carbapenem-resistant Enterobacteriaceae (CRE), carbapenem-resistant Acinetobacter (CRAB) and carbapenem-resistant pseudomonas aeruginosa(CRPA).

CEO Dennis Molnar said: “Helperby has developed a strong candidate for a longer lasting therapy effective against multiple drug- resistant infections. Helperby’s combination technique has the potential to extend the life of last-resort antibiotics which are under huge threat from antimicrobial resistance.”